sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes. DNA from isolates collected during the trial was used for genotype studies.The main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004.Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection. genotypes was also determined. 0.478).RTS,S/AS02A did not select for genotypes encoding...
Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine...
The development of an effective malaria vaccine has been hampered by the genetic diversity of common...
International audienceABSTRACT. The RTS,S/AS01 malaria vaccine confers only moderate protection agai...
sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotyp...
Objective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the...
OBJECTIVE: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the...
OBJECTIVE: RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast conta...
The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial...
RTS,S/AS02 is a recombinant protein malaria vaccine that contains a large portion of the C-terminal ...
The development of an effective malaria vaccine has been hampered by the genetic diversity of common...
The malaria vaccine candidate RTS,S/AS01 is based on immunogenic regions of Plasmodium falciparum ci...
The RTS,S/AS01 malaria vaccine encompasses the central repeats and C-terminal of Plasmodium falcipar...
The candidate malaria vaccine RTS,S/AS01E provides significant but partial protection from clinical ...
Objective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the...
The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial...
Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine...
The development of an effective malaria vaccine has been hampered by the genetic diversity of common...
International audienceABSTRACT. The RTS,S/AS01 malaria vaccine confers only moderate protection agai...
sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotyp...
Objective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the...
OBJECTIVE: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the...
OBJECTIVE: RTS,S, a candidate vaccine for malaria, is a recombinant protein expressed in yeast conta...
The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial...
RTS,S/AS02 is a recombinant protein malaria vaccine that contains a large portion of the C-terminal ...
The development of an effective malaria vaccine has been hampered by the genetic diversity of common...
The malaria vaccine candidate RTS,S/AS01 is based on immunogenic regions of Plasmodium falciparum ci...
The RTS,S/AS01 malaria vaccine encompasses the central repeats and C-terminal of Plasmodium falcipar...
The candidate malaria vaccine RTS,S/AS01E provides significant but partial protection from clinical ...
Objective: The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the...
The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial...
Partial protective efficacy lasting up to 43 months after vaccination with the RTS,S malaria vaccine...
The development of an effective malaria vaccine has been hampered by the genetic diversity of common...
International audienceABSTRACT. The RTS,S/AS01 malaria vaccine confers only moderate protection agai...